{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Fluarix+Trivalent",
    "query": {
      "intervention": "Fluarix Trivalent"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 185,
    "total_pages": 19,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Fluarix+Trivalent&page=2&page_size=10",
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-10-14T13:52:31.004Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT01091246",
      "title": "A Study to Evaluate the Immunogenicity of Quadrivalent Live Attenuated Influenza Vaccine (LAIV) in Children",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Healthy or Stable Chronic Illness"
      ],
      "interventions": [
        {
          "name": "Q/LAIV (MEDI3250)",
          "type": "BIOLOGICAL"
        },
        {
          "name": "FluMist/B/Yamagata",
          "type": "BIOLOGICAL"
        },
        {
          "name": "FluMist/B/Victoria",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "MedImmune LLC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "2 Years",
        "maximum_age": "17 Years",
        "sex": "ALL",
        "summary": "2 Years to 17 Years"
      },
      "enrollment_count": 2312,
      "start_date": "2010-03",
      "completion_date": "2010-12",
      "has_results": true,
      "last_update_posted_date": "2011-09-26",
      "last_synced_at": "2026-10-14T13:52:31.004Z",
      "location_count": 110,
      "location_summary": "Birmingham, Alabama • Mobile, Alabama • Tucson, Arizona + 95 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Mobile",
          "state": "Alabama"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Benton",
          "state": "Arkansas"
        },
        {
          "city": "Bentonville",
          "state": "Arkansas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01091246"
    },
    {
      "nct_id": "NCT01215734",
      "title": "Standard vs High-Dose Trivalent Inactivated Flu Vaccine in Adult Hematopoetic Stem Cell Transplant (HSCT) Recipients",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Adult Stem Cell Hematopoetic Transplant"
      ],
      "interventions": [
        {
          "name": "High-Dose Trivalent Inactivated Influenza Vaccine (HD-TIV)",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Standard Dose Trivalent Inactivated Flu Vaccine",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Vanderbilt-Ingram Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 44,
      "start_date": "2010-10",
      "completion_date": "2012-09",
      "has_results": true,
      "last_update_posted_date": "2013-03-08",
      "last_synced_at": "2026-10-14T13:52:31.004Z",
      "location_count": 1,
      "location_summary": "Nashville, Tennessee",
      "locations": [
        {
          "city": "Nashville",
          "state": "Tennessee"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01215734"
    },
    {
      "nct_id": "NCT00253734",
      "title": "Immunogenicity and Safety of Different Doses of Fluzone® Influenza",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Influenza"
      ],
      "interventions": [
        {
          "name": "Fluzone® (IM)",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Fluzone®",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)",
      "sponsor_class": "NIH",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "49 Years",
        "sex": "ALL",
        "summary": "18 Years to 49 Years"
      },
      "enrollment_count": 217,
      "start_date": "2005-11",
      "completion_date": "2006-11",
      "has_results": false,
      "last_update_posted_date": "2013-06-03",
      "last_synced_at": "2026-10-14T13:52:31.004Z",
      "location_count": 1,
      "location_summary": "St Louis, Missouri",
      "locations": [
        {
          "city": "St Louis",
          "state": "Missouri"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00253734"
    },
    {
      "nct_id": "NCT00461981",
      "title": "A Phase 2 Study to Evaluate Immune Responses of FluMist®",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Influenza Vaccine"
      ],
      "interventions": [
        {
          "name": "TIV, Trivalent Inactivated Influenza Virus Vaccine",
          "type": "BIOLOGICAL"
        },
        {
          "name": "FluMist, Influenza Virus Vaccine Live",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "MedImmune LLC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "12 Months",
        "maximum_age": "35 Months",
        "sex": "ALL",
        "summary": "12 Months to 35 Months"
      },
      "enrollment_count": 101,
      "start_date": "2007-05",
      "completion_date": "2008-02",
      "has_results": true,
      "last_update_posted_date": "2021-10-06",
      "last_synced_at": "2026-10-14T13:52:31.004Z",
      "location_count": 19,
      "location_summary": "Jonesboro, Arkansas • Little Rock, Arkansas • Anaheim, California + 16 more",
      "locations": [
        {
          "city": "Jonesboro",
          "state": "Arkansas"
        },
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Anaheim",
          "state": "California"
        },
        {
          "city": "West Palm Beach",
          "state": "Florida"
        },
        {
          "city": "Lexington",
          "state": "Kentucky"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00461981"
    },
    {
      "nct_id": "NCT04080531",
      "title": "Influenza Vaccination for Flu Prevention in Patients With Plasma Cell Disorders",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Plasma Cell Neoplasm"
      ],
      "interventions": [
        {
          "name": "Pneumococcal 13-valent Conjugate Vaccine",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Trivalent Influenza Vaccine",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Emory University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 165,
      "start_date": "2019-10-18",
      "completion_date": "2022-12-15",
      "has_results": true,
      "last_update_posted_date": "2025-02-28",
      "last_synced_at": "2026-10-14T13:52:31.004Z",
      "location_count": 2,
      "location_summary": "Atlanta, Georgia",
      "locations": [
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04080531"
    },
    {
      "nct_id": "NCT00283283",
      "title": "Comparison of Full-dose Flu Vaccine to Half-dose Flu Vaccine",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Influenza"
      ],
      "interventions": [
        {
          "name": "Fluzone® (Aventis Pasteur inactivated influenza vaccine)",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "U.S. Army Medical Research and Development Command",
      "sponsor_class": "FED",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "64 Years",
        "sex": "ALL",
        "summary": "18 Years to 64 Years"
      },
      "enrollment_count": 1316,
      "start_date": "2004-11",
      "completion_date": "2006-05",
      "has_results": true,
      "last_update_posted_date": "2021-02-12",
      "last_synced_at": "2026-10-14T13:52:31.004Z",
      "location_count": 2,
      "location_summary": "Washington D.C., District of Columbia",
      "locations": [
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        },
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00283283"
    },
    {
      "nct_id": "NCT00192192",
      "title": "Trial to Investigate Immune Responses Elicited by a Liquid Formulation of Influenza Virus Vaccine, Trivalent, Types A & B, Live Cold Adapted (CAIV-T) in Healthy Adults",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Influenza"
      ],
      "interventions": [
        {
          "name": "CAIV-T",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "MedImmune LLC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "64 Years",
        "sex": "ALL",
        "summary": "18 Years to 64 Years"
      },
      "enrollment_count": 20,
      "start_date": "2000-11",
      "completion_date": "2000-12",
      "has_results": false,
      "last_update_posted_date": "2021-09-13",
      "last_synced_at": "2026-10-14T13:52:31.004Z",
      "location_count": 1,
      "location_summary": "Stamford, Connecticut",
      "locations": [
        {
          "city": "Stamford",
          "state": "Connecticut"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00192192"
    },
    {
      "nct_id": "NCT01666782",
      "title": "Study Comparing High-Dose Flu Vaccine to Standard Vaccine in Cancer Patients Less Than 65 Receiving Chemotherapy",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Cancer",
        "Influenza Viral Infections"
      ],
      "interventions": [
        {
          "name": "Standard Trivalent Influenza Vaccine",
          "type": "BIOLOGICAL"
        },
        {
          "name": "High-Dose Influenza Vaccine",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Saad Jamshed MD",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "64 Years",
        "sex": "ALL",
        "summary": "18 Years to 64 Years"
      },
      "enrollment_count": 105,
      "start_date": "2012-08",
      "completion_date": "2015-12",
      "has_results": true,
      "last_update_posted_date": "2016-06-24",
      "last_synced_at": "2026-10-14T13:52:31.004Z",
      "location_count": 2,
      "location_summary": "Rochester, New York",
      "locations": [
        {
          "city": "Rochester",
          "state": "New York"
        },
        {
          "city": "Rochester",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01666782"
    },
    {
      "nct_id": "NCT01011049",
      "title": "Study of Influenza Vaccine Revaccination in Healthy Adults Previously Vaccinated With Fluzone ID or Fluzone IM",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Influenza"
      ],
      "interventions": [
        {
          "name": "Influenza Virus Vaccine USP Trivalent Types A and B",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Sanofi Pasteur, a Sanofi Company",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "64 Years",
        "sex": "ALL",
        "summary": "18 Years to 64 Years"
      },
      "enrollment_count": 1250,
      "start_date": "2009-09",
      "completion_date": "2010-10",
      "has_results": true,
      "last_update_posted_date": "2016-04-14",
      "last_synced_at": "2026-10-14T13:52:31.004Z",
      "location_count": 44,
      "location_summary": "Hoover, Alabama • Huntsville, Alabama • Mobile, Alabama + 38 more",
      "locations": [
        {
          "city": "Hoover",
          "state": "Alabama"
        },
        {
          "city": "Huntsville",
          "state": "Alabama"
        },
        {
          "city": "Mobile",
          "state": "Alabama"
        },
        {
          "city": "Chandler",
          "state": "Arizona"
        },
        {
          "city": "Mesa",
          "state": "Arizona"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01011049"
    },
    {
      "nct_id": "NCT01987349",
      "title": "T-cell And General Immune Response to Seasonal Influenza Vaccine (SLVP018) - Year 1, 2009",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Influenza"
      ],
      "interventions": [
        {
          "name": "Fluzone® (intramuscular)",
          "type": "BIOLOGICAL"
        },
        {
          "name": "FluMist® (intranasal)",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Stanford University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "8 Years",
        "maximum_age": "100 Years",
        "sex": "ALL",
        "summary": "8 Years to 100 Years"
      },
      "enrollment_count": 72,
      "start_date": "2009-09",
      "completion_date": "2010-01",
      "has_results": true,
      "last_update_posted_date": "2017-05-12",
      "last_synced_at": "2026-10-14T13:52:31.004Z",
      "location_count": 1,
      "location_summary": "Stanford, California",
      "locations": [
        {
          "city": "Stanford",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01987349"
    }
  ]
}